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Abstract 
Peptides from 10 to 22 amino acids containing sequences encompassed byStaphylococcus aureus protein A were synthesized. 
Some of these peptides, when present in cultures of lymphomononuclear cells from healthy donors or from cancer patients 
(melanoma, breast carcinoma, non-Hodgkin lymphoma nd renal cell carcinoma) promoted: (i) changes in the phenotype of the 
lymphomononuclear population, (ii) stimulation of monocytes (release of IL-1 and TNF-a), and (iii) an increase in cytotoxicity 
against K562, Daudi and HT-29 cells. Isolated monocytes responded also to those peptides with a release of IL-1 and TNFa and 
an increase of cytotoxicity against HT-29 cells. It was found that the active peptides had the following structural pattern: a length 
of at least 15 amino-acid residues with a proline at position 6, valine, leucine, isoleucine, glycine, alanine or lysine at position 2, 
and glutamic or aspartic acid at position 11. Replacement of Pro at position 6 with any other esidue turned the peptide inactive. 
Replacement of residues at positions 2 and 11 with amino-acid residues other than those required for activity resulted in 
compounds with a marked decrease in the immunomodulating properties described, or lacking these properties altogether. 
Key words: Immunomodulatory peptide; Cytotoxicity; Tumor necrosis factor a; Interleukin 1; Lymphomononuclear cell; 
Monocyte; (Human) 
I .  Introduction 
Protein A from Staphylococcus aureus (SPA) [1,2] 
has a wide variety of immunological properties, such as 
the stimulation of lymphocyte subpopulations, the re- 
lease of interferon and natural killer activity [3-7]. In 
general, exogenous antigens require processing by anti- 
gen presenting cells (APC) before their association 
with MHC proteins to form a complex that can be 
recognized by specific T cell receptors [8,9]. Helper T 
cells are stimulated by MHC class II molecules which 
generally present peptides from antigens that have 
entered B cells or macrophages by endocytosis [10]. T 
cells do not recognize native protein antigens, unless 
previously denatured or partially degraded, and subse- 
quently displayed in association with MHC class II (Ia) 
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molecules by APC. The pattern of peptide association 
with various allelic variants of Ia reflects the pattern of 
MHC restriction of the immune response [11,12]. The 
structural requirements for their interactions have been 
subjected to an intense investigation. Several models 
have been elaborated to predict T cell epitopes based 
on either the presence of amphipathic a-helixes [13], 
amino-acid sequence motifs [14], or structural similari- 
ties of MHC core-binding regions on previously identi- 
fied epitopes [15,16]. However, the binding of an im- 
munodominant peptide to a class II molecule is a 
necessary, but not sufficient condition to promote an 
immune response. 
We speculated that short synthetic peptides derived 
from SpA might have similar immunological properties 
to those exhibited by the native protein, and, if that 
were the case, that the possible correlation between 
those properties and the structural features of the 
active peptides could be established. We show below 
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that peptides derived from SpA are indeed biologically 
active and that their activity seems to be related to a 
common structural pattern. 
2. Materials and methods 
Cell source and preparations 
Peripheral blood mononuclear cells from healthy 
donors or from cancer patients, when indicated, were 
obtained by leukapheresis, using a Fenwall CS-3000 
continuous flow separator (Fenwall Laboratories, 
Deerfield, IL, USA). Vascular access was obtained 
with a double central venous catheter. Isolation and 
purification of monocytes was carried out following the 
technique described by Bcyum [17]. 
Cell culture conditions 
Peripheral blood mononuclear cells were cultivated 
at 2" 106 cells/ml in RPMI-1640 medium supple- 
mented with 2.5% of autologous erum, 200 mM L- 
glutamine, penicillin (100 U/ml), and streptomycin 
(100 ~g/ml)  in humidified atmosphere with 5% CO 2 
at 37°C. Peptides were added at a concentration f 20 
/~g/106 ceils; rlL-2 at 500 U/106 ceils and SpA at 20 
/zg/106 cells. 
Chemical synthesis of the peptides 
The synthesis of the various peptides was carried 
out by the solid-phase method of Merrifield [18], with 
the Fmoc modification [19]. 
Surface markers 
Immunofluorescence studies were performed with a 
Coulter Epics flow cytometer (Coulter Electronics, 
Hialeah, FL). The monoclonal antibodies used in this 
study were: anti-Leu-4 (CD3), Leu-2a (CD8), Leu-lla 
(CD16), Leu-19 (CD56), Leu-M3 (CD14) and HLA-DR, 
obtained from Becton-Dickinson Immunocytometry 
Systems, (Erembodegen, Belgium) and anti-MAC1 
(CDllb) from Immunotech (Marseilles, France). All 
these antibodies were used as conjugates of fluorescein 
isothiocyanate (FITC). Each assay was accompanied 
with its appropriate isotype control. 5" 105 cells were 
incubated in 50 /zl of PBS-0.1% BSA with the mono- 
clonal antibody during 30 min at 4°C. After incubation 
the cells were washed twice with cold PBS-0.1% BSA. 
Cells were then fixed in 500/~1 of formaldehyde in 2% 
PBS. Forward angle (FALS) and 90 ° light scattering 
(90 ° LS) measurements were recorded. 5000 cells were 
analyzed for each determination. The percentage of 
positive cells was determined after substraction ofnon- 
specific labelling events, which, in turn, were evaluated 
in each measurement with the corresponding isotype 
control. 
Cytokine determinations 
IL-1 and TNFa were measured by the quantitative 
'sandwich' enzyme immunoassay technique with com- 
mercially available kits (Quantikine, R&D Systems, 
Minneapolis, USA). 
Cytotoxicity assay 
The 4 h SlCr release cytolysis assay [20] was per- 
formed with K562 [21] and Daudi [22] cell lines as 
targets. Target cells (1" 104) were added to serially 
diluted ((50-5)" 104) effector ceils in RPMI containing 
2.5% autologous serum in round-bottomed microtiter 
plates. All determinations were carried out in tripli- 
cate. The percentage lysis was calculated by the for- 
mula ((experimental release- spontaneous release)/ 
(maximal cpm incorporated- spontaneous release))× 
100. The spontaneous 51Cr release from cell line tar- 
gets was always < 10%. Cytotoxicity associated with 
monocytes was measured following the technique of 
Meltzer [23] using purified monocytes or lymphomono- 
nuclear cells as effector cells, and HT-29 cells from a 
human adenocarcinoma [24] cultured in monolayer as 
target cells. HT-29 cells were labelled with 1 mCi/ml 
of [3H]thymidine when they had a confluence of 50% 
and incubated at 37°C for 16-18 h. The incubation 
with the effector cell was carried out at 37°C and 5% 
CO 2 • 
3. Results and discussion 
Cytotoxicity induced by synthetic peptides derived from 
SpA 
The amino-acid sequence of Cowan I strain 
staphylococcal protein (SPA) is already well established 
[1,2]. Peptides consisting of 15 amino acids (14 of them 
reflecting the sequence of the four Fc-binding regions 
(regions D, A, B and C of SpA as described by Sj6dahl 
[2]) were synthesized. The extra amino acid, always on 
the carboxyl end, was valine which was added for 
synthesis convenience. Table 1 shows the ability of 
synthetic peptides to induce cytotoxieity against tumor 
cell lines, Daudi and K562, when lymphomononuclear 
cells were incubated in their presence. IL-2 was used 
as a reference control. 
A close examination of the peptides reveals that all 
the active structures with regard to cytotoxieity include 
a proline residue at position 6 and a glutamic acid 
residue located at the 11th position. The nature of the 
amino-acid residues at positions 2 and 3 seems also to 
be of importance, position 2 being a leucine, isoleucine, 
valine or a lysine residue, and position 3 preferentially 
leucine. 
These results prompted us to synthesize new pep- 
tides introducing amino-acid substitutions in some of 
the active peptides derived from protein A. Table 2 
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Table 1 
Cytotoxicity induced by synthetic peptides, derived from SpA on 
lymphomononuclear cells from healthy donors 
Peptide Sequence a Position b Cytotoxicity 
No. Daudi K562 
1 ADAQQNKFNKDQQS 1 -14  --  --  
2 QNKFNKDQQSAFYE 5 -18  --  --  
3 KDQQSAFYE ILNMP 10-23  - - 
4 ADNNFNKEQQNAFY 62-75  --  --  
5 ADNKFNKEQQNAFY 120-133 --  --  
6 FNKD(I( ISA FYE I LN 8 -21  - -  - -  
7 FNKE( I ( INAFYE I LN 66-79  --  --  
8 FNKEQQNAFYE ILH 182-195 - -  --  
9 QSAFYE ILNMPMLN 13-26 - - 
I0  QNAFYE ILNMPNLN 71-84  --  - -  
11 ( INAFYE I  LHLPNLN 129-143 - - 
12 ( INAFYE ILHLPNLT  187-200 - -  - -  
13 E I  LNMPNLNEEQRN 18-31  + + + + 
14 E ILHLPNLNEEQRN 134-147 + + + + 
15 E ILHLPNLTEEQRN 192-205 + + + + 
16 MPNLNEEQRNGFIQ 22-35  - -  - -  
17 LPNLNEEQRNGFIQ 138-151 --  --  
18 LPNLTEEQRNGFIQ 196-209 --  --  
19 EEQRNGFIQSLKDD 27-40  - -  --  
20 GFIQSLKDDPSQST 32-45 - - 
21 GF IQSLK I ){ )PSQSA 90-103 - - 
22 GFIQSLKDDPSVSK 206-219 -- -- 
23 s LKOI )PSQSTNVLG 36-49  + + 
24 SLKDDPSQSANLLA 94-107 + + 
25 SLKDDPSVSKEILA  210-223 + + + + 
26 PSQSTNVLGEAKKL  41-54 - - 
27 PSQSANLLAEAKKL  99-112  --  --  
28 PSVSKEILAEAKKL 215-228 -- -- 
29 NVLGEAKKLNESQA 46-59  --  - -  
30 NLLAEAKKLNESQA 104-117 --  --  
31 NLLAEAKKLNDAQA 162-175 - - 
32 E I  LAEAKKLNDAQA 220-233 - -  - -  
33 KKLNESQAPKADNN 52-65 - - 
34 KKLNESQAPKADNK 110-123 - -  - -  
35 KKLNI )AQAPKAI}NN 168-181 --  --  
36 ESQAPKADNNFNKE 56-69  --  --  
37  ESQAPKADNKFNKE 114-127 - -  - -  
38 DAQAPKADNNFNKE 172-185 - - 
39 YE I  LNMPNLNEEQR 17-30 - - 
40 FYE ILNNPNLNEEQ 16-29  --  --  
41 QSLKDDPSVSKEIL  209-222 - -  --  
42 IQSLKDDPSVSKEI  208-221 - - 
43 F IQSLKOOPSVSKE 207-220 - - 
44 FYE ILHLPNLNEEQ 132-145 - - 
45 YE ILHLPNLTEEQR 191-204 --  --  
46 FYE ILHLPNLTEEQ 190-203 - -  --  
Peptides were scored for expressed cytotoxicity as follows: + +,  
good inducers; +,  intermediate inducers; - ,  non-inducers. Peptide 
concentration was always 20/xg /106 cells, rlL-2 at a concentration 
of 500 U /106  cells was used as a reference control. Cytotoxicity was 
determined after 7 days of incubation. 
a An extra valine residue, not shown, was added at the terminus for 
synthesis convenience, b Numbering of the amino-acid residue taken 
from Sjfdahl [2]. 
shows that the replacement of proline by alanine or 
glycine in the active peptides 13, 14, 15 or 25 resulted 
in inactive peptides. This confirmed the requirement of 
proline at the indicated position (peptides 47-53). 
However, the replacement at position 6 by proline in 
inactive peptides 54 and 55 was unable to render them 
active. Some other modifications were also introduced 
in inactive peptides. In peptide 29 (NVLGEAKKL- 
NESQA) Glu at position 5 was replaced by Ala, and 
Ala at position 6 by Pro. The resulting peptide (peptide 
56) was very active with regard to antitumor cytotoxic- 
ity against Daudi and K562 cells. Table 3 shows the 
cytotoxicity induced on lymphomononuclear cells by 
synthetic peptides resulting from modifications of pep- 
tide 56. The results showed that for a peptide of 15 
amino acids, the requirements for activity were: proline 
at position 6, glutamic acid at position 11, and leucine, 
isoleucine or valine at position 2. With the exception of 
peptide 25, in all active peptides tested, position 3 was 
always leucine. The peptides resulting from the re- 
placement of Val at position 2 of peptide 56 by Lys or 
a hydrophobic amino-acid residue were still active. 
However, this activity was rather low. The activity was 
also greatly reduced if Glu at position 11 was replaced 
by Asp. The replacement of an amino-acid residue at 
any position either to the right or to the left of proline 
at position 6 by proline resulted in inactive peptides. 
The non-Fc-binding region E of SpA contains also a 
sequence fulfilling the structural pattern of active pep- 
tides. The synthetic peptide QVLNMPNLNADQRNV, 
which contains 14 amino-acid residues of such a se- 
quence plus an extra valine at the C end, also induced 
cytotoxicity. 
The length of the peptide was also tested. Extended 
peptides containing the structure of an active peptide 
were also active. This was the case of peptides 
DQQSAFYEILNMPNLNEEQR (peptide 81, se- 
quence 11-30 in SpA) and NGFIQSLKDDPSVSKEI- 
LAEAK (peptide 82, sequence 205-226 in SPA). How- 
ever, peptides hortened from either the amino or the 
carboxyl end were inactive (data not shown). 
Table 2 
Effect of single amino-acid substitutions at position 6 on the cyto- 
toxic activity of synthetic peptides 
Peptide Sequence a Derived from Cytotoxicity 
No. wild peptide Daudi K562 
47 E ILNMANLNEEQRNV 13 (P  --, A )  
48 E I  LHLANLNEEQRNV 14(P~ A)  
49 E ILHLANLTEEQRNV 15 (P  ~A)  
50 E I  LNM6NLLEE( IRNV 13 (P --* G) 
51 SLKDD6SVSKEILAV 25 (P ~G)  
52 E ILHL6NLNEEQRNV 14 (P  --, G)  
53 EILHL6NLTEEQRNV 15 (P  --* G)  
54 YE ILHPPNLNEEQRV 45 (L  --* P)  
55 ADAQQPKFNKDQIQSV I (N - - *  P) 
q 
h 
Peptide concentration was always 20/zg/106 cells, rIL-2 at a concen- 
tration of 500 U/106 cells was used as a reference control. Cytotoxic- 
ity was determined after 7 days of incubation. 
a In bold: amino-acid replacement at position 6 of the wild peptide. 
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Table 3 
Cytotoxicity induced on lymphomononuclear cells from healthy 
donors following amino-acid replacement in the sequence of peptide 
56 
Peptide Sequence a Cytotoxicity 
No. Daudi K562 
56 NVLGAPKKLNESQAV + + + + 
57 NVLPAPKKLNESQAV + + 
58 N V L G A P K K P N E S Q A V  + + 
59 N T L G A P K K L N E S Q A V  + + 
60 N C L G A P K K L N E S Q A V  + + 
61 NKLGAPKKLNESQAV + + 
62 N F L G A P K K L N E S Q A V  - - 
63 N M L G A P K K L N E S Q A V  - -  - 
64 N Q L G A P K K L N E S Q A V  - -  - -  
65  N W L G A P K K L N E S Q A V  - -  - -  
66 N $ L G A P K K L N E S Q A V  - -  - 
67 N Y L G A P K K L N E S Q A V  - -  - 
68 N A L G A P K K L N E S Q A V  + + 
69 N 6 L G A P K K L N E S Q A V  + + 
70 N V L G A A K K L N E S Q A V  - -  - -  
71 N V L G A G K K L N E S Q A V  - - -  
72 N V L G A P K L L N K S Q A V  + - -  
73 N V L G A P K K L N V S Q A V  - -  - -  
74 N V L G A P K K L N D S Q A V  + + 
75 N V L G A P K K L N T S Q A V  - -  - -  
76 N V L G A P K K L N S S Q A V  - -  - -  
77 N V L G M P K K L N E S Q A V  + + 
78 N V L G E P K K L N E S Q A V  - -  - 
79 N K L G A P K K L N K S Q A V  + + 
80 NELGAPKKLNVSQAV - -  - -  
Peptide concentration was always 20/zg/106 cells, rlL-2 at a concen- 
tration of 500 U/106 cells was used as a reference control. Cytotoxic- 
ity was determined after 7 days of incubation. 
a In bold: amino-acid replacement respect to wild peptide 56. 
Table 4 shows the cytotoxicity induced by the most 
active peptides as well as that induced by SpA or IL-2. 
The cytotoxicity induced by the synthetic peptides 
against K562 cells was similar to that induced by IL-2 
or SpA. The activity against Daudi cells was slightly 
lower in the case of the synthetic peptides. SpA and 
active peptides also induced cytotoxicity against HT-29 
Table 4 
Peptide-induced cytotoxic activity against K562, Daudi and HT-29 
target cells 
Product ested Cytotoxic activity 
(% chromium release) (% [3H]thymidine 
release) 
Daudi K562 HT-29 
Medium 9±3 195:5 27±5 
Peptide No. 56 68 ± 6 63 5:8 62 ± 6 
Peptide No. 13 62+8 62.+7 59+_5 
Peptide No. 25 58 5:9 59 ± 9 57 -+ 5 
Peptide No. 81 56-+6 58_+7 58-+6 
Inactive peptide No. 2 10±4 12±8 29±4 
rlL-2 805:9 70-+6 n.d. 
SpA 745:9 68.+7 67_+5 
IFN7 n.d. n.d. 70_+ 5 
Lymphomononuclear cells were obtained from five different healthy 
donors. Results represent mean±S.E. SpA concentration was 20 
/zg/106 cells. Peptide concentration was always 20 /xg/106 cells. 
rlL-2 (500 U/106 cells) or IFN',/ (100 U/106 cells) were used as 
reference controls. Cytotoxicity was determined after 7 days of 
incubation. Effector-to-target c ll ratio was 50 : 1 for K562 and Daudi 
cells, and 20 : 1 for HT-29 cells, n.d., not determined. 
cells, reaching values similar to those obtained with 
IFN3, which was used as positive control. 
Phenotypes of lymphomononuclear cells after peptide 
stimulation 
Surface markers in the cell populations after incuba- 
tion in the presence of the active peptides were also 
studied. Table 5 shows the results obtained together 
with those corresponding to IL-2 or SpA. The percent- 
age of CD3 and CD8 remained constant in the differ- 
ent samples. However, the proportion of cells express- 
ing markers CDllb (NK, monocytes and macrophages) 
and CD14 (monocytes and macrophages) increased in 
the presence of SpA or active peptides. The percent- 
age of these markers remained unaltered in popula- 
tions incubated in the presence of inactive control 
Table 5 
Phenotypes of lymphomononuclear cells after peptide activation 
Product ested Cells expressing surface markers (%) 
CD3 CD8 CD11b CD14 CDI6 CD56 
Medium 59 5:3 17 5:2 14 + 4 9 5:1 11 5:5 6 5:2 
Peptide No. 56 60 5:1 17 ± 1 23 + 5 17 5:4 22 + 7 18 ± 6 
Peptide No. 13 58 5:2 18 5:2 24 ± 3 18 ± 3 22 + 6 17 ± 5 
Peptide No. 25 59 5:3 17 5:2 23 ± 4 18 ± 3 21 5:5 18 5:5 
Peptide No. 81 58 ± 3 18 ± 2 21 ± 3 17 ± 4 21 ± 6 17 ± 5 
Peptide No. 2 60 + 2 17 ± 2 13 ± 4 9 5:2 12 5:4 6 ± 2 
rlL-2 59 5:3 19 ± 2 13 5:2 6 ± 1 23 ± 4 25 +_ 3 
SpA 60 5:3 18 ± 1 23 5:4 16 ± 2 22 5:5 20 ± 4 
Lymphomononuclear cells were obtained from five different healthy donors. Results represent mean ± S.E. SpA concentration was 20 ~g/106 
cells. Peptide concentration was always 20/zg/106 cells, rlL-2 at a concentration f 500 U/106 cells was used as a reference control. Phenotypes 
were determined after 7 days of incubation. 
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Table 6 
Release of Interleukin-1 and Tumour Necrosis Factor a following 
addition of cytotoxic peptides or control substances 
Product ested Factor elease 
IL-1 TNFot TNFa 
(pg/10 6cells) (U/10 6 cells) +anti-TNFa 
Medium 12 4 4 
Peptide No. 56 68 89 16 
Peptide No. 13 62 65 12 
Peptide No. 25 39 63 10 
Peptide No. 81 39 71 12 
Peptide No. 2 5 7 6 
LPS 150 - - 
PMA - 540 17 
IL-2 5 5 6 
SpA 84 143 20 
Lymphomononuclear cells were obtained from five different healthy 
donors. Results represent mean+S.E.SpA concentration was 20 
/xg/106 cells. Peptide concentration was always 20 g,g/10 6 cells; 
rlL-2, 500 U//10 6 cells; LPS 10/zg/ml; PMA (100 nM). Incubation 
time, 24 h. 
pept ides,  or in the presence of IL-2. On the contrary, 
the expression of CD56 (NK and LAK)  was higher in 
cells incubated in the presence of  IL-2, than in the 
presence of SpA or active peptides.  CD16 (neutrophi ls,  
monocytes and NK) was e levated in all cell populat ions 
with respect o the incubated controls. 
Release of interleukin-1 and TNFa induced by synthetic 
peptides 
In order  to ascertain the possible st imulat ion of 
monocytes,  IL-1 and TNFa  were determined in the 
supernatants  after 24 h of  incubation. The results of 
Table 6 clearly show that both cytokines were re leased 
by cells incubated in the presence of e i ther SpA or the 
active pept ides.  As expected, no increase was observed 
in the supernatants  from cells incubated in the pres- 
ence of IL-2. L ipopolysaccar ide (LPS) and phorbol  
myristate acetate (PMA)  were used as positive con- 
trols. The nature of TNFa  re leased was also conf i rmed 
with ant i -TNFa  antibody. Prel iminary results show also 
that isolated monocytes incubated in the presence of 
active pept ides  responded with the product ion of IL-1 
and TNFa  in a t ime-dependent  fashion (data not 
shown). 
Cytotoxicity induced by active peptides on lym- 
phomononuclear cells from cancer patients 
The response to immunmodulat ing pept ides  was 
also studied in lymphomononuc lear  cells from cancer 
patients.  Table 7 shows that pept ides  13, 25 and 56, but 
not pept ide 2, used as a control,  induced an increase in 
cytotoxicity of  these cells against K562 and Daudi  cells. 
The values were lower than those el icited by IL-2. The 
changes of surface markers  were similar to those ob- 
served with cells obta ined from healthy donors (data 
not shown). 
Cytotoxicity induced by active peptides on isolated mono- 
cytes 
Isolated monocytes incubated for 5 days in the pres- 
ence of SpA or active pept ides  exhibited a cytotoxicity 
against HT-29 cells higher than those incubated in the 
presence of an inactive control  pept ide (Table 8). The 
opt imum effector-to-target cell rat io was 2 : 1. 
In conclusion, the results clearly show that a number  
of synthetic pept ides  can induce cytotoxicity against 
cells of tumoral  l ines K562 and Daudi  ceils (Tables 
1-4). The active pept ides  have a number  of features 
which can be summarized in the following pattern:  
R t-aa 1-aa 2-aaa-aa4-aa5-aa6-aa 7- 8-aaq-aa 10-aa 11-aa 12- 
aa 13-aa 14-aa 15-R 2 
Table 7 
Cytotoxicity induced by synthetic peptides on lymphomononuclear cells from cancer patients 
Patients Product ested 
Medium IL-2 SpA Peptide 
No. 13 No. 56 No. 25 No. 2 
(a) 
A 12 58 42 21 26 19 12 
B 7 46 56 49 44 52 12 
C 32 60 68 46 50 56 29 
D 6 88 56 39 41 48 12 
(b) 
A 3 98 67 40 58 50 6 
B 14 38 41 29 32 40 9 
C 21 48 61 36 46 43 18 
D 14 38 41 29 32 40 9 
SpA concentration was 20/zg/106 cells. Peptide concentration was always 20/xg/106 cells, rlL-2 at a concentration f 500 U/10  6 
as a reference control. Cytotoxicity was determined after 7 days of incubation. Effector cell/Target cell ratio was 50/1. The 
Chromium release of top (a) and bottom (b) panels were obtained against K562 and Daudi cells, respectively. 
Patients: A, melanoma (stage III); B, non-Hodgkin lymphoma; C, breast carcinoma; D, renal cell carcinoma. 
cells was used 
percentage of
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Table 8 
Cytotoxicity induced by synthetic peptides on isolated monocytes 
against HT-29 cells 
Product ested Cytotoxic activity 
(% [3H]thymidine r lease) 
Medium 20 + 3 
Peptide No. 56 60 +_ 4 
Peptide No. 13 56_+5 
Peptide No. 25 58 + 6 
Peptide No. 81 50+_ 4 
Inactive peptide No. 2 20 + 4 
SpA 62 + 6 
IFNT 73 + 5 
Monocytes were obtained from five different healthy donors. Results 
represent mean+ S.E. SpA concentration was 20/zg/106 cells. Pep- 
tide concentration was always 20 /zg/106 cells. IFN3, (100 U/106 
cells) was used as reference control. Cytotoxicity was determined 
after 5 days of incubation. Effector-to-target c ll ratio was 2:1. 
where aa 6 must be Pro, aa 2 can be Val, I le, Leu, Gly, 
A la  or Lys, and aa11 can be Glu or Asp.The activity of 
the pept ides  is mainta ined if R t = H and R 2 -- OH,  or 
if R 1 or R 2 are longer pept ide  chains as the ones 
found in SpA. 
The cytotoxicity seems to be mediated  by NK, LAK 
and monocytes as suggested by the cell markers  (Table 
5); effect on K562 cells (NK dependent) ,  Daud i  (LAK 
and NK dependent )  and HT-29 (monocyte dependent) ;  
and the release of IL-1 and TNFa  (Table 6). Zembala  
et al. [25] have proposed that the endogenous produc-  
t ion of TNFa  is possibly involved in the enhancement  
of ant igen presentat ion by monocytes in an autocr ine 
fashion. The TNFot release induced by the active pep-  
t ides discussed above could be an important  step in the 
immunopotent iat ing effects observed. 
These results allow also to hypothesize that the 
st imulat ion of  the dif ferent ceils involved in the re- 
sponse induced by the active pept ides  descr ibed could 
have been init iated through monocytes acting as APC.  
Cytotoxicity against K562 and Daud i  cells was also 
st imulated by the active pept ides  in lymphomononu-  
clear cells from a number  of cancer pat ients (Table 7). 
These results suggest the possibil ity of using these 
pept ides  as a potent ia l  cancer therapy. 
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